The Use of Splenectomy to Manage Platelet Transfusion Refractoriness Due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation | Zendy

Margherita Mauro | Zendy; Francesco Saverio Camoglio | Zendy; Pierluigi Piccoli | Zendy; Massimiliano De Bortoli | Zendy; Rita Balter | Zendy; Anna Pegoraro | Zendy; Simone Cesaro | Zendy

Open Access

The Use of Splenectomy to Manage Platelet Transfusion Refractoriness Due to Anti-Human Leukocyte Antibodies in Allogeneic Stem Cell Transplantation

Author(s) -

Margherita Mauro,

Francesco Saverio Camoglio,

Pierluigi Piccoli,

Massimiliano De Bortoli,

Rita Balter,

Anna Pegoraro,

Simone Cesaro

Publication year - 2016

Publication title -

pediatric reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.297

H-Index - 19

ISSN - 2036-7503

DOI - 10.4081/pr.2016.6159

Subject(s) - medicine , splenectomy , rituximab , platelet , antibody , platelet transfusion , hematopoietic stem cell transplantation , transplantation , immunology , haematopoiesis , stem cell , surgery , spleen , biology , genetics

In patients undergoing hematopoietic stem cell transplantation (HSCT), refractoriness to platelet transfusion has been associated with graft failure, delayed engraftment, early mortality and decreased overall survival. Therapeutic strategies include plasma exchange, immunoglobulins, rituximab, and splenectomy. We describe here three patients with refractoriness to platelet transfusion due to anti-human leukocyte antibodies who were splenectomized before HSCT (two cases) and after HSCT (one case) due to the lack of efficacy of other therapies. Splenectomy was uneventful. All three patients achieved a full donor engraftment. We suggest that splenectomy is feasible and effective in HSCT patients to reduce the risk of graft failure or delayed engraftment

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research